Boltwood Capital Management Purchases 1,205 Shares of Pfizer Inc. $PFE

Boltwood Capital Management boosted its position in Pfizer Inc. (NYSE:PFE) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,854 shares of the biopharmaceutical company’s stock after acquiring an additional 1,205 shares during the quarter. Boltwood Capital Management’s holdings in Pfizer were worth $1,402,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Quintet Private Bank Europe S.A. grew its stake in shares of Pfizer by 30.2% during the second quarter. Quintet Private Bank Europe S.A. now owns 468,523 shares of the biopharmaceutical company’s stock valued at $11,357,000 after buying an additional 108,608 shares during the last quarter. Teamwork Financial Advisors LLC grew its stake in shares of Pfizer by 28.8% during the second quarter. Teamwork Financial Advisors LLC now owns 64,438 shares of the biopharmaceutical company’s stock valued at $1,562,000 after buying an additional 14,398 shares during the last quarter. Wesbanco Bank Inc. grew its stake in shares of Pfizer by 10.6% during the second quarter. Wesbanco Bank Inc. now owns 214,238 shares of the biopharmaceutical company’s stock valued at $5,193,000 after buying an additional 20,474 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of Pfizer by 12.9% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 25,035 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 2,858 shares during the last quarter. Finally, Douglas Lane & Associates LLC grew its stake in shares of Pfizer by 2.0% during the second quarter. Douglas Lane & Associates LLC now owns 44,340 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 887 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $23.91 on Monday. The stock’s 50 day simple moving average is $24.79 and its two-hundred day simple moving average is $24.27. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.